Logo image of PTN

PALATIN TECHNOLOGIES INC (PTN) Stock Fundamental Analysis

NYSEARCA:PTN - US6960775020 - Common Stock

0.0941 USD
-0.08 (-44.65%)
Last: 5/7/2025, 8:04:01 PM
Fundamental Rating

2

PTN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 541 industry peers in the Biotechnology industry. PTN may be in some trouble as it scores bad on both profitability and health. PTN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

PTN had negative earnings in the past year.
PTN had a negative operating cash flow in the past year.
PTN had negative earnings in each of the past 5 years.
In the past 5 years PTN reported 4 times negative operating cash flow.
PTN Yearly Net Income VS EBIT VS OCF VS FCFPTN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -625.34%, PTN is doing worse than 97.15% of the companies in the same industry.
Industry RankSector Rank
ROA -625.34%
ROE N/A
ROIC N/A
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTN Yearly ROA, ROE, ROICPTN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K 20K -20K

1.3 Margins

PTN has a better Gross Margin (1255.00%) than 100.00% of its industry peers.
PTN's Gross Margin has declined in the last couple of years.
PTN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1255%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A
PTN Yearly Profit, Operating, Gross MarginsPTN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K

0

2. Health

2.1 Basic Checks

PTN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PTN has more shares outstanding
PTN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PTN has been reduced compared to a year ago.
PTN Yearly Shares OutstandingPTN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
PTN Yearly Total Debt VS Total AssetsPTN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

PTN has an Altman-Z score of -171.53. This is a bad value and indicates that PTN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PTN (-171.53) is worse than 98.22% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -171.53
ROIC/WACCN/A
WACC10.35%
PTN Yearly LT Debt VS Equity VS FCFPTN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.38 indicates that PTN may have some problems paying its short term obligations.
The Current ratio of PTN (0.38) is worse than 94.48% of its industry peers.
A Quick Ratio of 0.38 indicates that PTN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.38, PTN is doing worse than 94.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.38
PTN Yearly Current Assets VS Current LiabilitesPTN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.31% over the past year.
The Revenue for PTN has decreased by -95.07% in the past year. This is quite bad
PTN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -40.52% yearly.
EPS 1Y (TTM)40.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.57%
Revenue 1Y (TTM)-95.07%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%-100%

3.2 Future

PTN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.24% yearly.
Based on estimates for the next years, PTN will show a very strong growth in Revenue. The Revenue will grow by 162.67% on average per year.
EPS Next Y51.7%
EPS Next 2Y52.7%
EPS Next 3Y48.26%
EPS Next 5Y30.24%
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PTN Yearly Revenue VS EstimatesPTN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 0 100M 200M 300M 400M 500M
PTN Yearly EPS VS EstimatesPTN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 -4 -6

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTN. In the last year negative earnings were reported.
PTN is valuated cheaply with a Price/Forward Earnings ratio of 0.14.
Based on the Price/Forward Earnings ratio, PTN is valued cheaper than 99.64% of the companies in the same industry.
PTN is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.66, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.14
PTN Price Earnings VS Forward Price EarningsPTN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTN Per share dataPTN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PTN's earnings are expected to grow with 48.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.7%
EPS Next 3Y48.26%

0

5. Dividend

5.1 Amount

No dividends for PTN!.
Industry RankSector Rank
Dividend Yield N/A

PALATIN TECHNOLOGIES INC

NYSEARCA:PTN (5/7/2025, 8:04:01 PM)

0.0941

-0.08 (-44.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)05-20 2025-05-20/bmo
Inst Owners14.18%
Inst Owner Change-90.08%
Ins Owners0.72%
Ins Owner Change2.24%
Market Cap2.45M
Analysts80
Price Target7.14 (7487.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48%
Min EPS beat(2)24.29%
Max EPS beat(2)71.71%
EPS beat(4)3
Avg EPS beat(4)25.29%
Min EPS beat(4)-5.65%
Max EPS beat(4)71.71%
EPS beat(8)3
Avg EPS beat(8)-26.04%
EPS beat(12)6
Avg EPS beat(12)-12.52%
EPS beat(16)8
Avg EPS beat(16)-16.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-58.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)63.04%
EPS NY rev (1m)0%
EPS NY rev (3m)40.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.14
P/S 6.99
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.54
EYN/A
EPS(NY)0.69
Fwd EY729.86%
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0.01
BVpS-0.25
TBVpS-0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -625.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1255%
FCFM N/A
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.53%
Cap/Sales 1.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.38
Altman-Z -171.53
F-Score3
WACC10.35%
ROIC/WACCN/A
Cap/Depr(3y)120.27%
Cap/Depr(5y)96.16%
Cap/Sales(3y)9.17%
Cap/Sales(5y)16.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.57%
EPS Next Y51.7%
EPS Next 2Y52.7%
EPS Next 3Y48.26%
EPS Next 5Y30.24%
Revenue 1Y (TTM)-95.07%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%
EBIT growth 1Y1.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.15%
OCF growth 3YN/A
OCF growth 5YN/A